Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring

Originally posted on Abbott.com

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The devices bring new benefits to patients with heart rhythm disorders, including a patient-preferred design without compromising battery longevity and MRI compatibility.  In addition, the new devices offer Bluetooth technology and a new patient smartphone app for improved remote monitoring, allowing for increased patient/physician engagement and streamlined communications.

It is estimated that as many as 6.1 million people in the United States battle cardiac arrhythmias, or abnormal heart rhythms,1 and ICDs are used to help reduce the risks of life-threatening arrhythmias. For patients with heart failure or in situations when the heart’s chambers beat out of sync, CRT-Ds can be used to restore the heart’s natural pattern of beating.

“We are focused on developing and delivering life-changing technologies that impact patient care in a meaningful way,” said Randel Woodgrift, senior vice president, Cardiac Rhythm Management, Abbott. “The Gallant devices are the latest example of how Abbott is driving innovation to meet changing healthcare needs and helping to improve connectivity and engagement between patients and their doctors.”

The new Gallant system pairs with Abbott’s secure myMerlinPulse™, an iOS- and Android™- compatible mobile smartphone app that helps streamline communication between doctors and their patients. The app provides people with access to data, device performance, and transmission history, which helps them take an active role in their healthcare. Through the myMerlinPulse app, physicians can continuously monitor their patients remotely allowing for identification of asymptomatic episodes as well as patient-triggered transmissions, which can lead to earlier intervention and reduce clinical burden.

“The ability for patients to stay connected to their doctors via their implanted device and a smartphone app has the potential to change how healthcare providers and patients communicate with each other,” said Raffaele Corbisiero, M.D., FACC, director of electrophysiology and pacing at Deborah Heart and Lung Center, Browns Mills, N.J. “The FDA’s approval of Abbott’s Gallant devices enables doctors to provide a more collaborative approach to treatment plans and the increased bond between a patient and provider will lead to better outcomes for all.”

The Gallant system received CE Mark for use across Europe earlier this year.

For important safety information, please visit abbott.com.

Latest News

5 Biggest News Stories of the Week: October 6

As the saying goes, the news never stops — but there’s a lot of it out there, and all of it doesn’t always pertain to our readers. In this weekly news roundup, we’ll cover the top news stories that matter most to our diversity focused audience. 1. The Dollar Divide…

WOCA 2022 Research: How to Improve Representation of Women of Color in the Workplace 

Capital One and DiversityInc shared the results of their collaborative research report on women of color in the workplace at the 2022 annual Women of Color and Their Allies event held in Louisville on Sept. 21 in conjunction with Humana. Dr. Chris Parker, Head of Research & Data, DiversityInc, confirmed…

WOCA 2022: Executive Leaders Share Stories of Allyship for Women of Color

One of the best indicators of an organization’s success around diversity, equity and inclusion (DEI) is leadership accountability for DEI. At our 2022 Women of Color and Their Allies event, DiversityInc’s Head of Strategic Partnerships, Anita Ricketts, was joined on stage by leaders who are holding themselves and their contemporaries…

The Dollar Divide

Too Poor to Die: The Rising Cost of Funerals 

Death is expensive.  For more than two decades, I have extensively written and reported about money-related content and even I was surprised at the cost of my mother’s funeral.  The median cost of a funeral with a viewing and burial is approximately $7,848. That doesn’t include the cost of the…